New weapon against aggressive blood cancer shows promise
NCT ID NCT03004287
Summary
This study is testing whether adding a newer drug called daratumumab to the standard 'Total Therapy' approach helps patients with high-risk multiple myeloma live longer without their cancer getting worse. The trial involves 50 newly diagnosed patients who will receive the drug combination alongside chemotherapy and stem cell transplant. Researchers hope this approach will improve treatment effectiveness while potentially reducing side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
Conditions
Explore the condition pages connected to this study.